Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Nervous System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Nervous System Neoplasm

Cancer Family

Nervous System Neoplasm

CI-CAN-00000038Explore in graph →

Non-malignant1,523 active trials9 approved drugs210 evidence items

NCIt: C3268
MeSH: D009423

Overview
Statistics
Survival
Genomics48
Variants & evidence210
Drugs47
Trials5871
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (168)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 26–50 of 168 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma.
· N Engl J Med · 1993 · PMID 8441429 · validated civic_curation pubmed
Pediatric low-grade gliomas can be molecularly stratified for risk.
· Acta Neuropathol · 2018 · PMID 29948154 · validated civic_curation pubmed
BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma.
· Clin Cancer Res · 2011 · PMID 21610142 · validated civic_curation pubmed
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas.
· Nat Genet · 2013 · PMID 23583981 · validated civic_curation pubmed
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.
· Cancer Res · 2008 · PMID 18974108 · validated civic_curation pubmed
Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis.
· Cell Cycle · 2006 · PMID 17172831 · validated civic_curation pubmed
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs.
· Cell · 2016 · PMID 26919435 · validated civic_curation pubmed

Showing 26–50 of 168 publications

← Previous
1
2
3
…
7
Next →

Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups.

· Cancer Cell · 2015 · PMID 25965575 · validated civic_curation pubmed

Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms.

· Am J Surg Pathol · 2004 · PMID 15105654 · validated civic_curation pubmed

MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism.

· Nat Genet · 2016 · PMID 26829751 · validated civic_curation pubmed

Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation.

· Acta Neuropathol Commun · 2021 · PMID 33536079 · validated civic_curation pubmed

A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration.

· Acta Neuropathol · 2019 · PMID 31595312 · validated civic_curation pubmed

Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course.

· Acta Neuropathol · 2020 · PMID 31563982 · validated civic_curation pubmed

Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1.

· Proc Natl Acad Sci U S A · 2013 · PMID 23633565 · validated civic_curation pubmed

Childhood supratentorial ependymomas with YAP1-MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features.

· Brain Pathol · 2019 · PMID 30246434 · validated civic_curation pubmed

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).

· Neuro Oncol · 2022 · PMID 35395680 · validated civic_curation pubmed

Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis.

· Acta Neuropathol Commun · 2019 · PMID 30876455 · validated civic_curation pubmed

Supratentorial CNS-PNETs in children; a Swedish population-based study with molecular re-evaluation and long-term follow-up.

· Clin Epigenetics · 2023 · PMID 36895035 · validated civic_curation pubmed

Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era.

· PLoS One · 2012 · PMID 22479427 · validated civic_curation pubmed

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.

· Neurology · 2009 · PMID 19933982 · validated civic_curation pubmed

The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.

· Acta Neuropathol · 2010 · PMID 20127344 · validated civic_curation pubmed

Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.

· Cancer Res · 2003 · PMID 14583498 · validated civic_curation pubmed

The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.

· Neuro Oncol · 2015 · PMID 25910840 · validated civic_curation pubmed

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

· Neuro Oncol · 2015 · PMID 25586468 · validated civic_curation pubmed

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.

· Acta Neuropathol · 2013 · PMID 23904111 · validated civic_curation pubmed